Please login to the form below

Not currently logged in
Email:
Password:

Hisamitsu's Noven unit signs Brisdelle deal with Shionogi

Will co-promote the menopausal hot flushes treatment

Noven is to co-promote its menopausal hot flushes treatment Brisdelle (paroxetine) with Shionogi.

Noven, a US-based subsidiary of Hisamitsu Pharmaceutical, said the deal will help extend physician awareness of Brisdelle.

Brisdelle contains 7.5mg of paroxetine, which - at a slightly higher dose - is the active ingredient in antidepressants like GlaxoSmithKline's now off-patent Seroxat/Paxil. In common with Seroxat Brisdelle also carries a Boxed Warning about suicidality in its label.

In June the drug became the first and only FDA-approved non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause, commonly referred to as hot flushes.

It was approved to offer an alternative to treatments that contain either oestrogen alone or oestrogen plus a progestin and subsequently launched in November and marketed and sold through Noven Women's Health.

Now Shionogi's women's health sales force will promote Brisdelle in the US to a range of healthcare providers, including some primary care doctors, not currently detailed by the Noven's specialty sales force.

Jeffrey Eisenberg, Noven's president and CEO, said the agreement “recognises and builds upon the long-standing commitment of both companies to providing therapies to address the diverse needs of menopausal women”.

The deal, financial terms of which were not disclosed, will see Noven retain Brisdelle's commercial rights and continue to be principally responsible for its marketing, promotion and overall commercial strategy.

31st January 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....